Nature Reviews Drug Discovery (nature-reviews-drug-discovery)

Journal positioning

Nature Reviews Drug Discovery is a Springer Nature title and the field-defining review journal for drug discovery and development. Its defining character is authoritative, commissioned synthesis: it publishes no primary research, and the great majority of content is solicited by the editors from leaders in pharmacology, medicinal chemistry, translational medicine, and pharma R&D strategy. The journal rewards reviews and analyses that frame where a therapeutic area, target class, or development paradigm stands and where it is heading — integrating mechanism, clinical evidence, pipeline landscape, and commercial and regulatory context — rather than narrow methodological updates. Readership spans academic pharmacologists, biotech and pharma scientists, clinicians, and investors. This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Because most articles are commissioned, an unsolicited submission almost always begins with a pre-submission proposal. Before submitting, re-check the live author instructions on the Nature Reviews Drug Discovery site.

When to trigger

• The author is preparing a commissioned or proposed review on a drug target, modality, therapeutic area, or aspect of pharma R&D and names this journal as the venue.
• A manuscript synthesizes the state of drug discovery or development for a field — integrating biology, clinical data, and pipeline landscape — and the author is choosing between this journal and Nature Medicine, Nature Reviews Methods Primers, or Cell Reports Medicine.
• The author has a primary-research drug-discovery study and needs to be redirected, because this journal publishes no original data.
• The author needs the journal's commissioning norms, scope boundaries, and desk-reject criteria before drafting a proposal.

Scope & topic fit

• Target and pathway reviews: the biology, druggability, and clinical translation of a target class — kinases, GPCRs, ion channels, epigenetic regulators, protein-protein interactions — across discovery and development.
• Modality and platform reviews: small molecules, biologics, antibody-drug conjugates, cell and gene therapies, RNA therapeutics, PROTACs and targeted degraders, covering chemistry, delivery, and clinical maturity.
• Therapeutic-area landscapes: oncology, immunology, neurology, metabolic and infectious disease — synthesizing mechanism, the development pipeline, and unmet need.
• Drug discovery and development paradigms: AI/ML in discovery, translational biomarkers, clinical trial design innovation, drug repurposing, and the science of attrition and productivity.
• Regulatory, R&D-strategy, and pipeline analyses: approval trends, the economics of development, and data-driven assessments of where investment and innovation are concentrated.
• Mechanism-of-action and pharmacology reviews where the clinical-development implications are central, not incidental.

Method & evidence bar

• The central thesis must be identifiable in one or two sentences: a clear argument about the state and trajectory of a field, not an undifferentiated catalog of papers.
• Claims must be evidence-based and current: clinical-stage assertions should reflect the latest trial readouts and approval status, with pipeline data sourced and dated.
• Mechanistic claims must rest on the strongest available evidence; the review should weigh conflicting findings rather than report them uncritically.
• Figures and tables are a core deliverable: mechanism schematics, target/pipeline landscape tables, and trial-summary tables are expected to add synthesis, not merely illustrate.
• Quantitative analyses (approval rates, attrition, pipeline counts) must state data sources, cut-off dates, and methods so the numbers are reproducible.
• Where the review covers clinical evidence, it should reflect the relevant reporting and evidence standards (e.g., quality of underlying CONSORT-compliant trials, registration status) when appraising trial data.

Structure & house style

• Articles are commissioned; unsolicited work normally enters through a pre-submission proposal (synopsis, outline, author expertise) that the editors evaluate before inviting a full manuscript.
• Nature Reviews enforces defined length, display-item, and reference limits by article type (Review, Perspective, Analysis); re-check current limits on the live site.
• The writing is authoritative and accessible to a cross-disciplinary readership; jargon is explained, and the narrative builds an argument rather than surveying exhaustively.
• Display items carry much of the synthesis: schematic figures redrawn by the in-house art team, plus structured tables of targets, agents, and trials; authors supply clear source sketches and complete data.
• Boxes are used for self-contained background, definitions, or methodological asides so the main text keeps its narrative line.
• A structured summary and key-points list orient the reader; abstracts and headings follow the Nature Reviews template.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and ../../resources/official-source-map.md; start from the official source anchors for this journal family, then cite the current journal-specific page you checked.
• Search the live site for "Nature Reviews Drug Discovery for authors" / "submission guidelines" and follow the current Springer Nature version.
• Confirm the commissioning and pre-submission-proposal process; prepare a synopsis and outline rather than a full unsolicited manuscript unless invited.
• Re-check article-type definitions and the current word, display-item, and reference limits for Reviews, Perspectives, and Analyses.
• Re-check competing-interests disclosure (especially industry and consulting ties), funding statements, and AI-use disclosure; confirm any data-source citation requirements for pipeline/quantitative content.
• If the live official instructions conflict with this skill, the official instructions win.

Pre-submission self-check

• One sentence — the central argument about the field's state and trajectory, and why the readership needs it now.
• The work is a review/analysis, not primary research; no original experimental data are being reported as the contribution.
• A pre-submission proposal is prepared (or a commission is in hand) rather than an unsolicited full manuscript.
• Clinical and pipeline claims are current, sourced, and dated; quantitative figures state methods and cut-off dates.
• Display items are planned as synthesis (landscape/trial tables, mechanism schematics) with complete underlying data for the art team.
• Competing interests, especially industry relationships, are fully disclosed.

Common desk-reject triggers

• A primary-research manuscript reporting original experimental or clinical data, which the journal does not publish.
• An unsolicited full review submitted without a pre-submission proposal or editorial invitation.
• An undifferentiated literature survey with no central argument about where the field stands or is heading.
• A narrow, specialist update of interest only to a sub-field, lacking the cross-disciplinary significance the readership expects.
• Pipeline or quantitative claims without sourced, dated data, or clinical assertions that ignore the latest trial readouts and approvals.

Re-routing decision

• Primary clinical or translational research with original data on a therapy: Nature Medicine (nature-medicine).
• A methods-focused, reproducible how-to review of a discovery or development technique: Nature Reviews Methods Primers (nature-reviews-methods-primers).
• Primary translational or early-clinical drug studies in a medicine-focused venue: Cell Reports Medicine (cell-reports-medicine).
• A more specialist or mechanistic review of narrower scope: a society or subfield review journal (e.g., a pharmacology- or oncology-specific review title).

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] Nature Reviews Drug Discovery
[Topic tags] <2–3 closest topics>
[Method/evidence] <is there a single clear thesis on the field's state/trajectory, and is the synthesis current, sourced, and display-item-driven rather than a survey?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <commissioning/proposal process / article-type & length limits / competing-interest disclosure / pipeline-data sourcing / AI-use disclosure>
[Re-route suggestion] <if not a fit, a better-matched venue>